Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple MyelomaReportar como inadecuado

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BioMed Research International - Volume 2014 2014, Article ID 145843, 7 pages -

Clinical StudyDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo 519-763, Republic of Korea

Received 26 August 2014; Accepted 8 October 2014; Published 30 October 2014

Academic Editor: John B. Vincent

Copyright © 2014 Jae-Sook Ahn et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This retrospective study investigated the clinical efficacy and safety of bortezomib retreatment in patients with relapsed or refractory multiple myeloma MM. A total of 30 patients who relapsed or progressed after 6 months since the last dose of their previous bortezomib therapy were included in this study. During the median 6 cycles range: 2–12 of bortezomib retreatment, 10 33.3%, 2 6.7%, and 6 20.0% patients achieved complete response, very good partial response, and partial response, respectively. Grade 3 or 4 neutropenia 47.0%, thrombocytopenia 43.0%, anemia 10.0%, and peripheral sensory neuropathy 3.0% were observed. The median time to progression, progression-free survival, and overall survival were 5.8 months 95% CI: 2.6–9.0, 5.5 months 95% CI: 4.2–6.8, and 13.4 months 95% CI: 6.1–20.7, respectively. Patients who received bortezomib retreatment 12 months from initial last therapy had a 1-year OS rate of 65.8% 95% CI: 43.5–88.1 while patients receiving retreatment after 6–12 months interval had a 1-year OS rate of 41.7% 95% CI: 13.9–69.5 . In conclusion, this study demonstrates that retreatment with bortezomib is an effective strategy for patients with MM who relapsed at a long interval after initial bortezomib therapy.

Autor: Jae-Sook Ahn, Sung-Hoon Jung, Seung-Shin Lee, Seo-Yeon Ahn, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, and Je-Jung



Documentos relacionados